AbbVie (NYSE:ABBV) Trading Down 1% – Here’s What Happened

Shares of AbbVie Inc. (NYSE:ABBV) fell 1% during trading on Wednesday . The company traded as low as $260.31 and last traded at $263.08. Approximately 3,288,654 shares changed hands during trading, a decline of 52% from the average session volume of 6,798,994 shares. The stock had previously closed at $265.79.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: SKYRIZI Crohn’s disease expansion: AbbVie submitted an application to the European Medicines Agency for subcutaneous induction of SKYRIZI in adults with moderately to severely active Crohn’s disease. If approved, the formulation would provide an additional, potentially more convenient option alongside the existing intravenous induction treatment. The filing is supported by positive Phase 3 AFFIRM data and could strengthen AbbVie’s European immunology franchise. AbbVie Submits Regulatory Application to EMA for SKYRIZI Subcutaneous Induction
• Positive Sentiment: Defensive and dividend appeal: Investor-focused coverage continues to highlight AbbVie as a healthcare defensive stock with an established dividend, which may support demand during periods of economic or inflation uncertainty. When Inflation Is Sticky, 5 Dividend Aristocrats Are the Stocks to Own Now and Forever
• Neutral Sentiment: Coverage of Lilly and Roche’s FDA-cleared Alzheimer’s blood test focuses on healthcare diagnostics and related ETFs, rather than AbbVie’s business, so it is unlikely to have a direct effect on ABBV. FDA Nods Lilly-Roche’s Alzheimer’s Blood Test
• Neutral Sentiment: AbbVie’s immunology scholarship and patient-support initiative adds goodwill but has limited near-term financial significance. AbbVie’s Patient Support Scholarship Program
• Negative Sentiment: Valuation is a key risk: analysts are questioning whether AbbVie’s business can justify the premium after the stock’s sharp advance. Its elevated reported price-to-earnings ratio leaves less room for disappointment in growth, regulatory execution, or pipeline results. Has AbbVie Stock Become Too Expensive to Buy?

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ABBV shares. Cantor Fitzgerald upped their price objective on AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. UBS Group lifted their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Bank of America boosted their target price on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Evercore set a $235.00 price target on shares of AbbVie in a research report on Friday, May 15th. Finally, Citigroup raised their price target on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $275.95.

AbbVie Stock Down 1.8%

The company has a market cap of $456.24 billion, a price-to-earnings ratio of 72.95, a PEG ratio of 0.87 and a beta of 0.30. The firm has a 50 day moving average price of $251.87 and a two-hundred day moving average price of $228.68.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the previous year, the firm earned $2.97 earnings per share. The firm’s quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts expect that AbbVie Inc. will post 14.06 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a $1.73 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s payout ratio is 195.48%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On AbbVie

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie in the 4th quarter valued at about $28,000. Imprint Wealth LLC grew its stake in AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares during the period. Burk Holdings LLC bought a new stake in AbbVie in the second quarter worth approximately $30,000. Legacy Wealth Managment LLC ID increased its holdings in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new position in AbbVie in the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.